Literature DB >> 15622337

[Clinical, haemodynamic and genetic features of familial pulmonary arterial hypertension].

B Sztrymf1, J Francoual, O Sitbon, P Labrune, M Jambou, C Poüs, G Simonneau, M Humbert.   

Abstract

INTRODUCTION: Pulmonary arterial hypertension (PAH) is defined by a raised pressure in the pulmonary arterial circulation associated with small vessel narrowing due to proliferation of the endothelium and vascular smooth muscle. Idiopathic PAH should be distinguished from PAH associated with a causal disease. One familial type (familial PAH), gathered from one family, has recently been linked to a mutation of the BMPR 2 (bone morphogenetic protein receptor 2) gene. It seems important to compare the idiopathic form of PAH with these familial forms to confirm that the same diagnostic and therapeutic principles can be applied to familial PAH.
MATERIAL AND METHODS: The demographic, clinical, haemodynamic and prognostic data from 34 cases of familial PAH were compared with those of 451 cases of idiopathic PAH. The genetic characteristics of the familial forms were also defined.
RESULTS: Familial PAH presented at a younger age than idiopathic PH (31 +/- 15 vs. 45 +/- 18 years p=0.002) without any other demographic difference (sex-ratio 2.09/1 et 1.42/1 p=NS). There was no difference in exercises tolerance (6 minute walking test 341 +/- 98 and 289 +/- 135 metres p=NS), in haemodynamic parameters (mean PAP 65 +/- 12 and 62 +/- 15 mmHg, p=NS), or in prognosis, with the exception of an absence of a vasodilator response in the familial group to nitric oxide challenge. We found the BMPR 2 gene mutation to be quantitatively and qualitatively comparable to previously published data.
CONCLUSION: The only difference between these two forms of this illness were of a younger age at presentation and an absent vasodilator response in the familial PAH group. We do not propose that familial PAH should be treated any differently from the idiopathic form. Genetic counselling will need to be developed in line with the progress being made in the understanding of this condition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15622337     DOI: 10.1016/s0761-8425(04)71472-2

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  2 in total

1.  Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension.

Authors:  Elisabeth D Willers; John H Newman; James E Loyd; Ivan M Robbins; Lisa A Wheeler; Melissa A Prince; Krista C Stanton; Joy A Cogan; James R Runo; Daniel Byrne; Marc Humbert; Gerald Simonneau; Benjamin Sztrymf; Jane A Morse; James A Knowles; Kari E Roberts; Jude J McElroy; Robyn J Barst; John A Phillips
Journal:  Am J Respir Crit Care Med       Date:  2005-12-09       Impact factor: 21.405

2.  Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension.

Authors:  Zeynep Mutlu; Meral Kayıkçıoğlu; Sanem Nalbantgil; Özcan Vuran; Hatice Kemal; Nesrin Moğulkoç; Biray Ertürk; Hüseyin Onay; Zuhal Eroğlu; Hakan Kültürsay
Journal:  Anatol J Cardiol       Date:  2015-09-15       Impact factor: 1.596

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.